Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate Hemab Therapeutics “Moderate Buy”: Five of seven analysts recommend buying the stock, while one rates it a hold and one a sell. The average 12-month price target is $51.40, with several firms recently raising their targets.
• Institutional investors initiated notable positions: Citadel Advisors purchased approximately $19.2 million of shares, while State Street, Braidwell, Opaleye Management and Manufacturers Life Insurance also opened new stakes.
• The stock has declined amid weak results: COAG opened at $30.84, down sharply from its 50-day moving average of $45.06, and the company reported a quarterly loss of $0.80 per share versus the expected $0.63 loss.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $51.40.

Several research firms have recently issued reports on COAG. HC Wainwright lifted their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. Jefferies Financial Group raised their price objective on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Wedbush upped their target price on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings cut shares of Hemab Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a report on Friday, September 25th.

Hedge Funds Weigh In On Hemab Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp purchased a new stake in shares of Hemab Therapeutics in the 2nd quarter worth $2,825,000. Citadel Advisors LLC bought a new position in Hemab Therapeutics in the 2nd quarter worth $19,226,000. Opaleye Management Inc. purchased a new position in Hemab Therapeutics during the second quarter valued at $1,750,000. Braidwell LP bought a new stake in Hemab Therapeutics during the second quarter valued at about $5,877,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Hemab Therapeutics during the second quarter valued at about $688,000.

Hemab Therapeutics Stock Down 5.4%

COAG opened at $30.84 on Thursday. The stock has a market capitalization of $1.44 billion and a PE ratio of -1.24. The company's 50 day simple moving average is $45.06. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, analysts forecast that Hemab Therapeutics will post -3.09 earnings per share for the current fiscal year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.

Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.